Background: Clinical trial data have shown apremilast, an oral phosphodiesterase-4
inhibitor, to be efficacious and safe for the treatment of psoriasis. However, little real-world …

Apremilast is an oral selective phosphodiesterase-4 inhibitor developed recently for
psoriasis treatment. The aim of this study is to assess the real-life outcomes of use of …

Background: Apremilast is an oral phosphodiesterase 4 (PDE4) inhibitor used for the
treatment of moderate to severe psoriasis. Long-term data on the effectiveness and drug …

Introduction: Apremilast is an oral phosphodiesterase inhibitor, approved for moderate to
severe psoriasis in adults. Despite the advancement in dermatology, and the introduction of …

Background: Apremilast is a new oral drug for the treatment of moderate to severe plaque
psoriasis that reduces inflammation by inhibiting phosphodiesterase 4. Its efficacy and safety …

Apremilast is a novel oral phosphodiesterase 4 inhibitor effective for psoriasis. It regulates
the production of pro‐inflammatory mediators. Apremilast was approved in December 2016 …

Introduction: Psoriasis is a chronic inflammatory skin disease characterized by erythematous
plaques on extensor surfaces, scalp, and back. Current therapies for psoriasis are limited by …

Background The evidence for adding small-molecule drugs to an ongoing biologic treatment
is sparse, but combination therapies appear to be advantageous in appropriately selected …

Apremilast, an oral phosphodiesterase-4 inhibitor, is approved for use in the management of
psoriasis and psoriatic arthritis. Although its efficacy and safety have been well established …

Introduction Patients with mild-to-moderate plaque psoriasis often experience reduced
quality of life and increased disease burden due to itch or involvement of psoriasis in special …